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Abstract
Background
The Siewert classification system for gastroesophageal junction adenocarcinoma
has provided morphological and topographical information to help guide surgical decision
making. Evidence has shown that Siewert I and III tumors are distinct entities with
differing epidemiologic and histologic characteristics and distinct patterns of disease
progression, requiring different treatment. Siewert II tumors share some of the
characteristics of types I and III lesions, and the surgical approach is not universally agreed
upon. Appropriate surgical options include transthoracic esophagogastrectomy, transhiatal
esophagectomy, and transabdominal extended total gastrectomy.
Purpose
A review of the available evidence of the surgical management of Siewert II tumors
is presented.
Conclusions
Careful review of the data appear to support the fact that a satisfactory oncologic
resection can be achieved via a transabdominal extended total gastrectomy with a slight
advantage in terms of perioperative complications, and overall postoperative quality of life.
Overall and disease free survival compares favorably to the transthoracic approach. These
results can be achieved with careful selection of patients balancing more than just the
Siewert type in the decision making but considering also: preoperative T and N stage,
histological type (diffuse type requiring longer margins that are not always achievable via
gastrectomy), and presence of Barrett’s esophagus.
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Introduction
While there has been a decline in the incidence of adenocarcinoma of the distal
stomach, adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, and
gastric cardia have increased by 4-10% per year among males in the United States since
1976 [1,2]. The rise of adenocarcinoma of the distal esophagus and stomach in the United
States strongly contrasts to parts of East Asia, where gastric cancer is endemic, and lower
esophageal cancer rates continue to grow [3]. These epidemiological changes have been
linked to several factors that include the rise of obesity worldwide, as well as increasing
rates of gastroesophageal reflux and Barrett’s esophagus [4,5]. Obesity has been implicated
as the inciting risk factor in almost 40% of esophageal adenocarcinoma and more than 20%
of gastric cardia adenocarcinoma worldwide [6].
In an attempt to improve the diagnosis and guide the treatment of these tumors, J.R.
Siewert developed a topographic-anatomic subclassification of adenocarcinoma of the GE
junction as a result of seminal research from the 1980s and 1990s [7,8,9]. Specifically,
Siewert and Stein defined adenocarcinoma of the GE junction as tumors with their centers
within 5 centimeters proximal or distal to the anatomic cardia. It is critically important to
understand that the anatomic landmark in this classification is defined endoscopically, as
the oral end of the gastric folds, and not at the Z-line. These tumors were further divided
into three types: type I (arising between 1 and 5 cm proximal to the GE junction) usually
develop from an area with specialized intestinal metaplasia of the esophagus (Barrett’s
esophagus); type II (located within 1cm proximal and 2cm distal to the gastric cardia) are
true adenocarcinoma of the cardia arising from the cardiac epithelium or short segments
with intestinal metaplasia at the GE junction, and type III tumors (arising more than 2cm
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distal to the GE junction) are subcardial gastric adenocarcinoma which infiltrate the GE
junction and distal esophagus from below [10]. This classification system is further
illustrated in Figure 1 [11].
The management of these tumors has evolved from surgical resection alone to more
recently including adjuvant and neoadjuvant therapies for locally advanced disease. [12].
The ability of preoperative chemoradiation to increase the rates of R0 resection, as well as
positively impact survival has been demonstrated in the CROSS trial. This trial compared
neoadjuvant chemoradiotherapy plus surgery was compared to surgery alone for
resectable esophageal and GE junctional cancer [13]. A recent Cochrane review suggested
that perioperative chemotherapy for resectable gastroesophageal adenocarcinoma
increased survival compared to surgical resection alone [14]. Surgical resection remains
the backbone of the treatment for GE junction tumors, and tumor location has traditionally
guided which operative procedure to utilize.
Based on retrospective review of their large experience, Siewert and his group
concluded that type I tumors should be treated with an esophagectomy, while type II and
III tumors should be managed with an extended total gastrectomy [15]. This position has
come into question in recent years with many groups treating type II tumors more
similarly to esophageal adenocarcinoma [11]. It is very telling to note that the 8th edition of
the TNM classification classifies Siewert III with gastric cancer, whereas it maintains
Siewert I and II as being staged with esophageal cancer [16]. A recent international survey
among members of the International Society for Diseases of the Esophagus, the World
Organization for Specialized Studies on Disease of the Esophagus, and the International
Gastric Cancer Association showed that there are discrepancies in the surgical
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management of these tumors even among experts in the field. While this study was
internationally based, it did include a preponderance of European surgeons. 93% of
surgeons preferred esophagectomy for Siewert I tumors, while an extended gastrectomy
was favored in 66% of cases for Siewert II tumors. For type III tumors, gastrectomy was
preferred by 90% of the surgeons [17].
This article reviews the current available evidence regarding type II
adenocarcinoma of the gastric cardia with a focus on identifying those factors that may
guide the clinician to opt for the surgical technique that may provide the best perioperative
outcomes, oncologic results, and quality of life.

Siewert Type II Adenocarcinoma
Most of the controversy surrounding the management of GE junction
adenocarcinomas stems from the fact that these tumors share epidemiologic, histologic,
and anatomic characteristics with both esophageal and gastric cancers. Type II tumors
show a predilection for males, with a 4.8:1 male to female ratio, and rates of associated
intestinal metaplasia (Barrett’s) are around 10% [8]. As compared to type I tumors, where
lymph node involvement in the mediastinum reached 50%, type II tumors, mediastinal
nodes were involved in only 11% of patients in one large series [15]. Further
characteristics of these tumors based on Siewert classification are summarized in Table 1
[10,18].
We know that despite advances in neoadjuvant and adjuvant treatments, the
backbone of multimodality therapy is an adequate R0 resection with adequate LN
sampling. Surgical options to be considered for type II tumors include transthoracic
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esophagectomy, transhiatal esophagectomy, a left thoracoabdominal
esophagogastrectomy, or a total gastrectomy with extended distal esophageal resection. An
assessment of superiority for these techniques must include: oncologic efficacy,
perioperative outcomes, overall and disease-free survival, as well as quality of life. Once
favored by some groups, proximal gastrectomy is not presently considered among accepted
options for treatment due concerns related to oncologic outcomes and poor postoperative
quality of life.
Of note, the left thoracoabdominal esophagogastrectomy has been compared to
transabdominal total gastrectomy in a randomized controlled trial from the Japan Clinical
Oncology Group (ten-year follow-up data have become recently available). The study was
stopped after the first interim analysis due to inferiority of the left thoracoabdominal
resection in terms of safety and the group recommended against the use of this approach
for carcinoma of the gastric cardia [19].

Oncologic Efficacy
The keys to an oncologically successful surgical resection include obtaining an R0
resection as well as an adequate lymph node harvest.
Resection Margins
One challenge in obtaining an R0 resection with tumors at the gastric cardia is the
ability to obtain an adequate proximal margin on the esophagus. Classic teaching advocates
for a proximal negative margin of a minimum of 5 cm.
Barbour et al studied whether the length of the proximal resection margin and/or
the operative approach utilized, had any impact on survival by comparing patients who
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underwent either esophagectomy or extended gastrectomy for Siewert II carcinoma. The
authors identified an ex vivo margin length of 3.8 centimeters (that translates to
approximately a 5cm in vivo margin) correlated with improved survival. When comparing
operative approach, they noted median resection margins of 2.0 cm in the gastrectomy
group compared to 5.5 cm the esophagectomy group (p < 0.0001), with overall survival
being slightly favored in the esophagectomy group [20]. It is worth noting that the
gastrectomy cohort was statistically significantly older, presented with a higher pathologic
stage, and had significantly more positive lymph nodes.
A subsequent study from Mine et al reporting on extended gastrectomy for treating
Siewert type II (66%) and III (34%) demonstrated a very low R1 resection rate (1.4%) and
improved survival with a proximal resection margin of 2.0cm ex vivo, and 3.0 cm in vivo
[21]. These authors were careful to consider for gastrectomy only patients that had less
than 3 cm of esophageal involvement on preoperative imaging.
The most recent evidence on the relevance of a proximal margin > 5 cm comes from
the US Gastric Cancer Collaborative. In a report that describes data accumulated from 7
centers in the US, including 162 patients from 2000 to 2012 (Siewert II and III were
included - cancers of the cardia or GE junction comprised 67.6% of the population), the
authors found that proximal margin length was not associated with local recurrence or
overall survival. They concluded that efforts to achieve a specific proximal margin,
especially if it necessitated an esophagectomy, should be abandoned. [22]
These studies indicate that a shorter proximal resection length may prove to be an
adequate oncologic margin. Evidence from the literature suggests that the issue of margins
cannot be resolved with absolute measures but has to be based on several other factors
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including: histological type, with diffuse type requiring longer margins, presence of
Barrett’s esophagus, T stage, lymph node metastases, and E-cadherin expression, with
negative expression requiring longer margins [21,23].

Lymph Node Metastases
The argument of whether a thoracic approach should be used for Siewert type II
cancers has, at times, been based on the potential risk of leaving positive nodes behind via
a transabdominal approach, and thus “under-staging” a patient. One of the earlier
descriptions of the pattern of lymph node metastasis for these tumors was provided by
Siewert’s group examining a case series of over 1500 patients. In patients with type I
tumors with N+ disease, 50% had lower mediastinal nodal metastases, and 15% had upper
mediastinal nodal metastases. By contrast, in type II tumors, lower mediastinal nodal
involvement was implicated in only 12% of lymph node metastases. Only 6% of type III
tumors that metastasized had subsequently spread to the mediastinum [24]. This is further
highlighted in Figure 2.
Not surprisingly, the distance from the tumor to the GE junction seems to be an
indicator of metastasis to the mediastinal lymph nodes. In a recent study by Kurokawa et
al, rates of metastasis or recurrence were significantly higher when the distance from the
GE junction to the proximal edge of the tumor was greater than 3 centimeters for upper
and middle mediastinal nodes, and greater than 2 centimeters for the lower mediastinal
nodes [25]. A more recent report from the same group, looking specifically at
clinicopathologic characteristics and prognostic factors of type II tumors found that rates of
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metastases to the lower mediastinal lymph nodes was relatively high (16.1%), as were
metastases to the para-aortic lymph nodes (16.1%) [26].
A systematic review regarding lymph node metastases in GE junction
adenocarcinomas recently confirmed that the most commonly involved lymphatic stations
are locoregional (subdiapragmatic, along the left gastric, splenic, and hepatic vessels), and
that survival was improved when lymph nodes metastases remained in the locoregional
nodes. Rates of metastasis to the lower mediastinal nodal stations ranged from 7.5% to
23.8%, while upper mediastinal nodal stations were involved in less than 4% [27]. These
authors pointed out the relevance of the total number of lymph nodes harvested, over
specific stations, as being linked to overall survival. The 5-year follow up data from the
Dutch trial – that compared transthoracic and transhiatal esophagectomy for Siewert type I
and II – confirmed unequivocally that there is no benefit to be derived from an extended
lymphadenectomy for type II disease [28].
While many questions, remain and some conflicting reports may be the result of
different biology of disease between the eastern and western countries, some conclusions
can be made. Taken together, these data suggest that type II tumors preferentially
metastasize to the intraabdominal lymph nodes, but the lower mediastinal compartment
should be routinely sampled during the dissection of Siewert type II tumors. However,
when they do metastasize to mediastinal nodes, this is a predictor of poorer outcomes, and
the location relative to the primary tumor is paramount. The distance of the proximal
margin of the cancer from the GE junction appears to be a relevant factor in the decision to
pursue a transthoracic or a transabdominal approach.
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Perioperative Outcomes
Siewert and his colleagues compared short-term morbidity and mortality of
extended gastrectomy versus transhiatal esophagectomy for type II tumors. The authors
found a 1.9% mortality in the extended gastrectomy group compared to 5.6% in the
esophagectomy group. Despite the differences in mortality favoring extended gastrectomy,
following multivariate analysis, the single most important prognostic factor impacting
survival, was attaining an R0 resection [29].
A recent database analysis from the University of Kentucky using the American
College of Surgeons National Surgical Quality Improvement Project (ACS-NSQIP) and the
Surveillance Epidemiology and End Results (SEER) databases looked at a head-to-head
comparison of esophagectomy and total gastrectomy for type II tumors. When examining
1181 patients from the NSQIP database, the authors found no significant differences in
length of stay (10.5 days in gastrectomy, 10.0 in esophagectomy, p=0.46), morbidity
(33.2% in gastrectomy, 35% in esophagectomy, p=0.62), and thirty-day mortality (3.7% in
gastrectomy, 2.4% in esophagectomy, p=0.26) [30].

Long-term Outcomes
The results of the Dutch trial have been briefly mentioned before. Omloo et al
reported on a five-year follow-up of a randomized clinical trial comparing transthoracic
and transhiatal esophagectomy for types I and II tumors. In a subgroup analysis for type II
tumors, there was only a negligible difference in overall five-year survival—31% following
transhiatal esophagectomy and 27% following transthoracic esophagectomy (p = 0.81)
[28].
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Long-term oncologic outcomes were also examined by Martin et al. in their SEER
database analysis. Unadjusted median overall survival favored esophagectomy (26.0 vs.
21.0 months, p = 0.025), but with multivariate analysis, surgical approach was not an
independent predictor of overall survival. Notably, a higher percentage of patients
underwent multimodality therapy in the group that underwent esophagectomy versus
gastrectomy (42.9% vs. 29.6%, p < 0.001). The authors of this study concluded that
multimodality therapy and tumor biology more so than surgical approach impacted the
oncologic outcomes for Type II tumors [30].

Qualtiy of Life
Patient-centered outcomes, with a specific interest in post-operative quality of life
(QOL), are very important considerations in patients undergoing major gastroesophageal
resections. A recent study looked at long-term QOL comparing extended gastrectomy
versus transthoracic esophagectomy for GE junction adenocarcinoma. The authors looked
at 123 patients with a standardized QOL questionnaire, and then a specific QOL instrument
for esophageal cancer specific symptoms. When compared to a reference population of
healthy volunteers, predictably both esophagectomy and gastrectomy fared worse in
almost every category at two years following surgery. In a head-to-head comparison,
extended gastrectomy with D2 lymphadenectomy had statistically significant advantages in
physical function (p=0.04), dyspnea (p=0.02), and reflux (p=0.03). All other surveyed areas
provided no significant differences between the two operations [31].
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Beyond the Siewert Classification
The Siewert classification has provided the surgical community with a powerful tool
to guide decision making for a very challenging subgroup of cancers. It relies heavily on
accurate preoperative characterization. Generally staging of adenocarcinomas of the GEJ is
accomplished through endoscopic ultrasound (EUS) and computed tomography (CT).
These studies yield information regarding tumor location, depth of invasion, and evidence
of nodal disease. Unfortunately, neither are particularly accurate in tumor localization. In
particular, for Siewert II tumors, EUS localized tumors 66% of the time, and CT 57% of the
time, as compared to final pathology [32]. Unfortunately, the best techniques currently
available frequently may fail in accurately localizing a tumor by Siewert location, and thus
inaccurately guide surgical therapy. Data from the Dutch trial demonstrated that there was
significant migration of patients from having a type I tumor on preoperative endoscopy to
having a type II tumor on final pathology. There were 180 patients classified as type I on
preoperative endoscopic assessment but only 90 patients were confirmed type I on final
path [28].
Review of the available data presented above, seem to point to the fact that a careful
and meticulous preoperative identification of the tumor location with respect to the GE
junction, accurate staging and consideration of the biologic features of the cancer (Lauren
classification [33], presence of intestinal metaplasia) are key in determining the best
surgical approach to Siewert II disease. Emerging immune-histochemical techniques,
including but not limited to the expression of the proto-oncogene Her2 - expressed in a
subset of patients - may likely add to the available data and guide the clinician in their
decision making [34].
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Conclusions
There are evident conflicts in the available literature that are the result of several
levels of bias. Surgeons from different parts of the world have radically different
philosophical approaches to this disease, possibly the result of only partially known
epidemiological differences, and the available data is mixed as it frequently combines Type
II and III together. For these reasons, final considerations are difficult to make. Any
technique chosen for the surgical resection of type II tumors should have the same goals:
achieving a negative margin, performing an adequate lymphadenectomy, limiting the
perioperative morbidity and mortality of the operation, and attaining optimal patientcentered quality of life. Based on the above review of the evidence, there appears to be a
slight advantage to undergoing extended gastrectomy over esophagectomy for Siewert
type II adenocarcinomas in the right subgroup of patients, when an oncologically radical
procedure can be completed. The choice of surgical technique should not be based solely
on anatomic location, but should rely on careful evaluation by a multidisciplinary team
while considering endoscopic features, staging results, and histologic features.
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